Abstracts Archive - Page 1572 of 2607 - ACR Meeting Abstracts

Abstract Number: 2771 • 2017 ACR/ARHP Annual Meeting
NOMID-Associated Complications in Mice Are Prevented By CDD-450, a Small Molecule Inhibitor of the Mitogen-Activated Protein Kinase-Activated Protein Kinase 2 (MK2) Pathway
Gabriel Mbalaviele¹, Chun Wang¹, Susan Hockerman², Jon Jacobsen², Jeff Hirsch², Steve Mnich², Heidi Hope², Matt Saabye², Hal Hoffman³ and Joseph Monahan², ¹Medicine, Washington University School of Medicine,, St. Louis, MO, ²Confluence Life Sciences, Inc, St. Louis, MO, ³University of California, San Diego, San Diego, CA
Background/Purpose: NLRP3-activating mutations cause cryopyrinopathies of which NOMID is the most severe phenotype. NLRP3 assembles a protein complex, responsible for the maturation of IL-1β and…
Abstract Number: 2772 • 2017 ACR/ARHP Annual Meeting
Unbound IL-18 Distinguishes Human Macrophage Activation Syndrome from Familial Hemophagocytic Lymphohistiocytosis and Affects Innate Versus Adaptive Murine Lymphocytes Differently
Paul Tsoukas¹, Eric Weiss², Dirk Holzinger³, Charlotte Girard⁴, Dirk Foell⁵, Alexei A. Grom⁶, Sandra Ammann⁷, Stephan Ehl⁷, Eduardo Schiffrin⁸, Adriana Almeida de Jesus⁹, Raphaela Goldbach-Mansky⁹, Cem Gabay¹⁰ and Scott Canna¹¹, ¹Pediatric Rheumatology, Children’s Hospital of Pittsburgh, Pittsburgh, PA, ²RK Mellon Institute, Children’s Hospital of Pittsburgh, Pittsburgh, PA, ³Department of Pediatric Rheumatology and Immunology, University of Muenster, Muenster, Germany, ⁴Division of Rheumatology, Department of Internal Medicine Specialties, University Hospital of Geneva, Geneva, Switzerland, ⁵University of Muenster, Muenster, Germany, ⁶Pediatric Rheumatology, Cincinnati Children’s Hospital, Cincinnati, OH, ⁷Center for Chronic Immunodeficiency, Faculty of Medicine, University of Freiburg, Freiburg, Germany, ⁸AB2 Bio, Lausanne, Switzerland, ⁹Translational Autoinflammatory Disease Studies (TADS), Laboratory of Clinical Investigation and Microbiology (LCIM), NIAID/NIH, Bethesda, MD, ¹⁰SCQM, Geneva, Switzerland, Geneva, Switzerland, ¹¹Richard King Mellon Foundation Institute for Pediatric Research, Children's Hospital of Pittsburgh, Pittsburrgh, PA
Background/Purpose: Persistently and extremely elevated serum IL-18 has been associated with Macrophage Activation Syndrome (MAS). Chronic IL-18 is hypothesized to contribute to excessive interferon (IFN)-g…
Abstract Number: 2773 • 2017 ACR/ARHP Annual Meeting
Severe Juvenile Arthritis Associated with a De Novo Gain-of-Function Germline Mutation in MYD88
Keith A. Sikora¹, Joshua R. Bennett², Laurens Vyncke³, Zuoming Deng⁴, Wanxia Li Tsai², Ewald Pauwels⁵, Gerlinde Layh-Schmitt², April D. Brundidge², Fatemeh Navid², Kristien Zaal⁶, Eric Hanson², Massimo G. Gadina⁷, Louis M. Staudt⁸, Thomas A. Griffin⁹, Jan Tavernier³, Frank Peelman³ and Robert Colbert², ¹Pediatric Translational Research Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ²National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ³Department of Biochemistry, Ghent University, Ghent, Belgium, ⁴Biodata Mining & Discovery, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ⁵Center for Molecular Modeling, Ghent University, Ghent, Belgium, ⁶Light Imaging Section, Office of Science and Technology, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ⁷Translational Immunology, Office of Science and Technology, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ⁸National Cancer Institute, National Institutes of Health, Bethesda, MD, ⁹Levine Children’s Hospital at Carolinas Medical Center, Charlotte, NC
Background/Purpose: Using whole exome sequencing, we discovered a de novo heterozygous germline mutation in MYD88 (myeloid differentiation primary response 88) (c.666T>G, p.S222R) in a child…
Abstract Number: 2774 • 2017 ACR/ARHP Annual Meeting
Activation of a Cytosolic DNA Sensor Pathway in the Etiopathogenesis of Sjögren’s Syndrome
Harini Bagavant¹, Joanna Papinska¹, Grezgorz Gmyrek¹, Magdalena Sroka¹, Indranil Biswas², Sai Tummala² and Umesh S Deshmukh¹, ¹Arthritis and Clinical Immunology Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Oklahoma Medical Research Foundation, Oklahoma City, OK
Background/Purpose: Patients with Sjögren’s syndrome (SjS) often present with a heightened type I IFN response. Recognition of DNA within the cytosol by a multitude of…
Abstract Number: 2775 • 2017 ACR/ARHP Annual Meeting
Critical Role of Neutrophil Extracellular Traps (NETs) in Patients with Behcet’s Disease
Alexandre LE JONCOUR^1,2, Stephane Loyau³, Nicolas Lelay⁴, Marie-Christine Bouton⁵, Antoine Dossier⁶, Anne-Claire Desbois⁷, Fanny Domont⁸, Thomas Papo⁹, Martine Jandrot-Perrus⁵, Patrice Cacoub¹⁰, Nadine Ajzenberg⁵, David saadoun⁷ and Yacine Boulaftali², ¹Département Hospitalo-Universitaire Inflammation-Immunopathologie-Biotherapie (DHU i2B), F-75005, Paris, France., National center for Autoimmune and Systemic rare diseases and for Autoinflammatory diseases, Paris, France, ²INSERM 1148, CHU Xavier Bichat, paris, France, ³Unité INSERM 1148, CHU Xavier Bichat, Faris, France, ⁴2. Unité INSERM 1148, CHU Xavier Bichat, paris, France, ⁵Unité INSERM 1148, CHU Xavier Bichat, paris, France, ⁶3. Service de Médecine Interne, CHU Xavier Bichat, paris, France, ⁷Département Hospitalo-Universitaire Inflammation-Immunopathologie-Biotherapie, National center for Autoimmune and Systemic rare diseases and for Autoinflammatory diseases, Paris, France, ⁸Département Hospitalo-Universitaire Inflammation-Immunopathologie-Biotherapie, National center for Autoimmune and Systemic rare diseases and for Autoinflammatory diseases, paris, France, ⁹Service de Médecine Interne, CHU Xavier Bichat, Paris, France, ¹⁰Département de Médecine Interne et Immunologie Clinique, National center for Autoimmune and Systemic rare diseases and for Autoinflammatory diseases, Paris, France
Background/Purpose: Behçet's disease (BD) is a chronic systemic vasculitis characterised by muco-cutaneous, ocular, gastrointestinal, cerebral recurrent lesions. Venous thrombosis, is a frequent and life-threatening complication.…
Abstract Number: 2776 • 2017 ACR/ARHP Annual Meeting
Plasmacytoid Dendritic Cells in Systemic Fibrosis: Pathogenic Role in Bleomycin-Induced Fibrosis Model and Correlation with Disease in Patients with Systemic Sclerosis
Suzanne Kafaja¹, Isela Valera², Anagha Divekar³, Rajan Saggar⁴, Dinesh Khanna⁵, Daniel E. Furst⁶ and Ram R. Singh⁷, ¹Department of Internal Medicine, University of California Los Angeles, David Geffen School of Medicine, Division of Rheumatology, Los Angeles, CA, ²Autoimmunity and Tolerance Laboratory, Division of Rheumatology, Department of Medicine, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, CA, ³Biolegend, Sa Diego, CA, ⁴Medicine, University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, ⁵University of Michigan, Ann Arbor, MI, ⁶David Geffen School of Medicine at UCLA, Los Angeles, CA, ⁷Autoimmunity and Tolerance Laboratory, Department of Medicine/Rheumatology, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, CA
Background/Purpose: Fibrosis is the end-result of most inflammatory conditions, but its pathogenesis remains unclear. Studies in patients and animal models suggest a role for T-cells…
Abstract Number: 2777 • 2017 ACR/ARHP Annual Meeting
Factors Associated with Readiness for Adopting Osteoporosis Treatment Change
Maria I. Danila¹, Elizabeth J. Rahn², Amy S. Mudano¹, Ryan C. Outman³, Peng Li⁴, David T. Redden⁴, Fred A. Anderson⁵, Susan L. Greenspan⁶, Andrea Z. LaCroix⁷, Jeri W. Nieves⁸, Stuart L. Silverman⁹, E.S. Siris¹⁰, Nelson B. Watts¹¹, Sigrid Ladores¹², Karen Meneses¹², Jeffrey R. Curtis³ and Kenneth Saag³, ¹University of Alabama at Birmingham, Birmingham, AL, ²Department of Medicine, Division of Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ³Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁴Department of Biostatistics, University of Alabama at Birmingham, Birmingham, AL, ⁵University of Massachusetts Medical School, Worcester, MA, ⁶Medicine, University of Pittsburgh, Pittsburgh, PA, ⁷Group Health Cooperative, Seattle, WA, ⁸Helen Hayes, West Haverstraw, NY, ⁹Cedars-Sinai Medical Center, Los Angeles, CA, ¹⁰Columbia University Medical Center, New York, NY, ¹¹University of Cincinnati, Cincinnati, OH, ¹²Nursing, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Understanding factors associated with the readiness for adopting osteoporosis treatment change may inform the design of behavioral interventions to improve osteoporosis treatment uptake in…
Abstract Number: 2778 • 2017 ACR/ARHP Annual Meeting
Preventing Rheumatoid Arthritis: North American Perspectives of Patients and First-Degree Relatives on the Risk of Developing the Disease and of Potential Preventative Interventions
Mark Harrison¹, Luke Spooner², Marie Hudson³, Katherine Milbers⁴, Cheryl L. Koehn⁵, Axel Finckh⁶ and Nick Bansback⁷, ¹Pharmaceutical Sciences, University of British Columbia, Vancouver, BC, Canada, ²University of British Columbia, Vancouver, BC, Canada, ³Division of Rheumatology, Jewish General Hospital, Lady David Institute for Medical Research, Montreal, QC, Canada, ⁴Centre for Health Evaluation and Outcomes Sciences, Vancouver, BC, Canada, ⁵Arthritis Consumer Expert, Vancouver, BC, Canada, ⁶University Hospital of Geneva, Geneva, Switzerland, ⁷School of Population and Public Health, University of British Columbia, Vancouver, BC, Canada
Background/Purpose: Increasingly, evidence suggests that treatment of people at risk of rheumatoid arthritis (RA) with anti-rheumatic drugs could prevent the onset of disease. Ongoing randomized…
Abstract Number: 2779 • 2017 ACR/ARHP Annual Meeting
The Patient Perspective on Bdmard Dose Reduction: A Mixed Methods Study
L.M. Verhoef¹, E.M.H. Selten¹, J.E. Vriezekolk¹, A.J.L. de Jong², F.H.J. van den Hoogen^1,3, A.A. Den Broeder^1,3 and M.E.J.L. Hulscher⁴, ¹Rheumatology, Sint Maartenskliniek, Nijmegen, Netherlands, ²Department of Rheumatology, Rijnstate Arnhem, Arnhem, Netherlands, ³Rheumatology, Radboud university medical centre, Nijmegen, Netherlands, ⁴Radboud Institute for Health Sciences, IQ healthcare, Radboud university medical centre, Nijmegen, Netherlands
Background/Purpose: biological DMARDs (bDMARDs) are effective in the treatment of RA, but are also associated with side-effects and high costs. Dose reduction of bDMARDs, after…
Abstract Number: 2780 • 2017 ACR/ARHP Annual Meeting
Preference Phenotypes Can be Used to Support Shared Decision Making at the Point-of-Care
Liana Fraenkel¹, Pauline Binder-Finnema², Betty Hsiao², Carole Wiedmeyer³, George Michel² and W. Benjamin Nowell⁴, ¹Rheumatology, Rheumatology, Yale University School of Medicine, New Haven, CT, New Haven, CT, ²Yale University School of Medicine, New Haven, CT, ³CreakyJoints/Global Health Living Foundation, Upper Nyack, NY, ⁴Global Healthy Living Foundation, Upper Nyack, NY
Background/Purpose: Many important treatment decisions for patients with rheumatoid arthritis (RA) are conditional on patient preferences and mandate a shared decision making (SDM) approach. Furthermore,…
Abstract Number: 2781 • 2017 ACR/ARHP Annual Meeting
Assessing RA Disease Activity with Promis Measures Using Smartphone Technology
Huifeng Yun¹, Shuo Yang², W. Benjamin Nowell³, Cooper Filby¹, Lang Chen¹ and Jeffrey R. Curtis⁴, ¹University of Alabama at Birmingham, Birmingham, AL, ²Division of Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ³Global Healthy Living Foundation, Upper Nyack, NY, ⁴Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Health information technology has enabled efficient measurement of PROs using Computer Adaptive Testing (CAT) methods, which have been shown to minimize missing data and…
Abstract Number: 2782 • 2017 ACR/ARHP Annual Meeting
Patient Beliefs and Preference to Initiate a Proposed Medication in Rheumatoid Arthritis
Richard W Martin¹, Rohit Nallani², Andrew D Head¹, Aaron T Eggebeen¹, James D Birmingham¹ and Eric T Slavin¹, ¹Medicine, Rheumatology, Michigan State University, College of Human Medicine, Grand Rapids, MI, ²Michigan State University, College of Human Medicine, Grand Rapids, MI
Background/Purpose : Normative economic theory assumes that people making decisions have complete information of the options, rationally weigh the opportunity costs, expected outcomes and optimize…
Abstract Number: 2783 • 2017 ACR/ARHP Annual Meeting
Medications Associated with Osteoporotic Fracture Risk in Patients with Rheumatoid Arthritis
Gulsen Ozen¹, Sofia Pedro², Frederick Wolfe² and Kaleb Michaud¹, ¹Rheumatology, University of Nebraska Medical Center, Omaha, NE, ²National Data Bank for Rheumatic Diseases, Wichita, KS
Background/Purpose: Osteoporotic (OP) fractures are a major cause of disability, cost, and mortality in RA. Besides increased OP fracture risk, chronic inflammation and pain predispose…
Abstract Number: 2784 • 2017 ACR/ARHP Annual Meeting
Are We over-Testing for Liver Enzyme Abnormalities in Rheumatoid Arthritis Patients Prescribed Methotrexate?
Chi Chi Lau¹, Syeda Maria Sayeed¹, Amanda Kennedy², Joan Skelly³ and Sheldon Cooper⁴, ¹Rheumatology/ Medicine, University of Vermont, Burlington, VT, ²Internal Medicine, University of Vermont, Burlington, VT, ³Biostatistics, University of Vermont, Burlington, VT, ⁴Department of Medicine/Rheumatology, University of Vermont, Burlington, VT
Background/Purpose: Methotrexate (MTX) is a first line drug for Rheumatoid Arthritis (RA) that is associated with elevated liver function tests (LFTs) in 10- 20%…
Abstract Number: 2785 • 2017 ACR/ARHP Annual Meeting
Serious Infections Associated with Tofacitinib in Rheumatoid Arthritis Patients Previously Treated with Methotrexate
Marina Amaral de Avila Machado¹, Cristiano S. Moura², Steve Ferreira Guerra¹, Jeffrey R. Curtis³, Michal Abrahamowicz⁴, Hassan Behlouli¹ and Sasha Bernatsky⁵, ¹Department of Medicine, McGill University Health Centre, Montreal, QC, Canada, ²1Division of Clinical Epidemiology, McGill University Health Centre, Montreal, QC, Canada, ³Rheumatology & Immunology, University of Alabama at Birmingham, Birmingham, AL, ⁴Department of Medicine, McGill University Health Centre, Montreak, QC, Canada, ⁵Divisions of Rheumatology and Clinical Epidemiology, McGill University Health Centre, Montreal, QC, Canada
Background/Purpose: Little is known about the real-world safety of tofacitinib, an oral Janus kinase inhibitor. We compared serious infections associated with tofacitinib, disease-modifying antirheumatic drugs…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].